219 related articles for article (PubMed ID: 26218744)
1. Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer.
Xiao K; Li YP; Wang C; Ahmad S; Vu M; Kuma K; Cheng YQ; Lam KS
Biomaterials; 2015 Oct; 67():183-93. PubMed ID: 26218744
[TBL] [Abstract][Full Text] [Related]
2. KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-A for targeted neuroendocrine cancer therapy.
Chen G; Jaskula-Sztul R; Harrison A; Dammalapati A; Xu W; Cheng Y; Chen H; Gong S
Biomaterials; 2016 Aug; 97():22-33. PubMed ID: 27156249
[TBL] [Abstract][Full Text] [Related]
3. Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery.
Li Y; Xiao K; Luo J; Xiao W; Lee JS; Gonik AM; Kato J; Dong TA; Lam KS
Biomaterials; 2011 Sep; 32(27):6633-45. PubMed ID: 21658763
[TBL] [Abstract][Full Text] [Related]
4. Thailandepsin A-loaded and octreotide-functionalized unimolecular micelles for targeted neuroendocrine cancer therapy.
Jaskula-Sztul R; Xu W; Chen G; Harrison A; Dammalapati A; Nair R; Cheng Y; Gong S; Chen H
Biomaterials; 2016 Jun; 91():1-10. PubMed ID: 26994874
[TBL] [Abstract][Full Text] [Related]
5. The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth.
Weinlander E; Somnay Y; Harrison AD; Wang C; Cheng YQ; Jaskula-Sztul R; Yu XM; Chen H
J Surg Res; 2014 Jul; 190(1):191-7. PubMed ID: 24679699
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
7. A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer.
Wang XS; Kong DJ; Lin TY; Li XC; Izumiya Y; Ding XZ; Zhang L; Hu XC; Yang JQ; Gao SG; Lam KS; Li YP
Acta Pharmacol Sin; 2017 Jun; 38(6):931-942. PubMed ID: 28552907
[TBL] [Abstract][Full Text] [Related]
8. Facile construction of bioreducible crosslinked polypeptide micelles for enhanced cancer combination therapy.
Ruttala HB; Chitrapriya N; Kaliraj K; Ramasamy T; Shin WH; Jeong JH; Kim JR; Ku SK; Choi HG; Yong CS; Kim JO
Acta Biomater; 2017 Nov; 63():135-149. PubMed ID: 28890258
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
Li LH; Zhang PR; Cai PY; Li ZC
Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y
Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655
[TBL] [Abstract][Full Text] [Related]
12. Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice.
Joung KE; Min KN; An JY; Kim DK; Kong G; Sheen YY
Cancer Res; 2006 May; 66(10):5394-402. PubMed ID: 16707467
[TBL] [Abstract][Full Text] [Related]
13. Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma.
Xiao K; Liu Q; Al Awwad N; Zhang H; Lai L; Luo Y; Lee JS; Li Y; Lam KS
Nanoscale; 2018 May; 10(17):8207-8216. PubMed ID: 29682647
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.
Li ZH; Zhang XB; Han XQ; Feng CR; Wang FS; Wang PG; Shen J; Shi YK
Oncol Rep; 2013 Jul; 30(1):499-505. PubMed ID: 23624828
[TBL] [Abstract][Full Text] [Related]
15. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
[TBL] [Abstract][Full Text] [Related]
16. Tumor accumulation and antitumor efficacy of docetaxel-loaded core-shell-corona micelles with shell-specific redox-responsive cross-links.
Koo AN; Min KH; Lee HJ; Lee SU; Kim K; Kwon IC; Cho SH; Jeong SY; Lee SC
Biomaterials; 2012 Feb; 33(5):1489-99. PubMed ID: 22130564
[TBL] [Abstract][Full Text] [Related]
17. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
18. In situ diselenide-crosslinked polymeric micelles for ROS-mediated anticancer drug delivery.
Deepagan VG; Kwon S; You DG; Nguyen VQ; Um W; Ko H; Lee H; Jo DG; Kang YM; Park JH
Biomaterials; 2016 Oct; 103():56-66. PubMed ID: 27372421
[TBL] [Abstract][Full Text] [Related]
19. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
[TBL] [Abstract][Full Text] [Related]
20. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
